NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor

被引：90

作者：

Beria, Italo ^{[1
]}

Bossi, Roberto T. ^{[1
]}

Brasca, Maria Gabriella ^{[1
]}

Caruso, Michele ^{[1
]}

Ceccarelli, Walter ^{[1
]}

Fachin, Gabriele ^{[1
]}

Fasolini, Marina ^{[1
]}

Forte, Barbara ^{[1
]}

Fiorentini, Francesco ^{[2
]}

Pesenti, Enrico ^{[1
]}

Pezzetta, Daniele ^{[2
]}

Posteri, Helena ^{[1
]}

Scolaro, Alessandra ^{[1
]}

Depaolini, Stefania Re ^{[1
]}

Valsasina, Barbara ^{[1
]}

机构：

[1] Nerviano Med Sci Srl, Business Unit Oncol, I-20014 Nerviano, MI, Italy

[2] Accelera Srl, I-20014 Nerviano, MI, Italy

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2011年 / 21卷 / 10期

关键词：

PLK1; Polo-like kinase; Kinase inhibitor; In vivo activity; Phase I clinical trials; CANCER; BINDING; PROTEIN; PLK1;

D O I：

10.1016/j.bmcl.2011.03.054

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

As part of our drug discovery effort, we identified and developed 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as PLK1 inhibitors. We now report the optimization of this class that led to the identification of NMS-P937, a potent, selective and orally available PLK1 inhibitor. Also, in order to understand the source of PLK1 selectivity, we determined the crystal structure of PLK1 with NMS-P937. The compound was active in vivo in HCT116 xenograft model after oral administration and is presently in Phase I clinical trials evaluation. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：2969 / 2974

页数：6

共 50 条

[1] 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitors
Beria, Italo
Valsasina, Barbara
Brasca, Maria Gabriella
Ceccarelli, Walter
Colombo, Maristella
Cribioli, Sabrina
Fachin, Gabriele
Ferguson, Ronald D.
Fiorentini, Francesco
Gianellini, Laura M.
Giorgini, Maria L.
Moll, Jurgen K.
Posteri, Helena
Pezzetta, Daniele
Roletto, Fulvia
Sola, Francesco
Tesei, Dania
Caruso, Michele
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (22) : 6489 - 6494
[2] Identification of 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazoline Derivatives as a New Class of Orally and Selective Polo-Like Kinase 1 Inhibitors
Beria, Italo
Ballinari, Dario
Bertrand, Jay Aaron
Borghi, Daniela
Bossi, Roberto Tiberio
Brasca, Maria Gabriella
Cappella, Paolo
Caruso, Michele
Ceccarelli, Walter
Ciavolella, Antonella
Cristiani, Cinzia
Croci, Valter
De Ponti, Anna
Fachin, Gabriele
Ferguson, Ronald Dale
Lansen, Jacqueline
Moll, Jurgen Karl
Pesenti, Enrico
Posteri, Helena
Perego, Rita
Rocchetti, Maurizio
Storici, Paola
Volpi, Daniele
Valsasina, Barbara
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (09) : 3532 - 3551
[3] Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors
Zhao, Hui
Hu, Xiaoxia
Cao, Kai
Zhang, Yue
Zhao, Kuantao
Tang, Chunlei
Feng, Bainian
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 157 : 935 - 945
[4] Molecular Modeling Studies of 4,5-Dihydro-1H-pyrazolo[4,3-h] quinazoline Derivatives as Potent CDK2/Cyclin A Inhibitors Using 3D-QSAR and Docking
Ai, Yong
Wang, Shao-Teng
Sun, Ping-Hua
Song, Fa-Jun
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2010, 11 (10) : 3705 - 3724
[5] Polo-like kinase 1 inhibitor NMS-P937 represses nasopharyngeal carcinoma progression via induction of mitotic abnormalities
Gao, Jing
Huang, Weirong
Zhao, Senxia
Wang, Rong
Wang, Zhilin
Ye, Juanping
Lin, Lie
Cai, Weifeng
Mi, Yanjun
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2024, 38 (01)
[6] Identification of N,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor
Brasca, Maria Gabriella
Amboldi, Nadia
Ballinari, Dario
Cameron, Alexander
Casalc, Elena
Cervi, Giovanni
Colombo, Maristella
Colotta, Francesco
Croci, Valter
D'Alessio, Roberto
Fiorentini, Francesco
Isacchi, Antonella
Mercurio, Ciro
Moretti, Walter
Panzeri, Achille
Pastori, Wilma
Pevarello, Paolo
Quartieri, Francesca
Roletto, Fulvia
Traquandi, Gabriella
Vianello, Paola
Vulpetti, Anna
Ciomei, Marina
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (16) : 5152 - 5163
[7] Synergistic apoptotic effect of miR-183-5p and Polo-Like kinase 1 inhibitor NMS-P937 in breast cancer cells
Kudo, Masahisa
Zalles, Nicole
Distefano, Rosario
Nigita, Giovanni
Veneziano, Dario
Gasparini, Pierluigi
Croce, Carlo M.
CELL DEATH AND DIFFERENTIATION, 2022, 29 (02): : 407 - 419
[8] Synergistic apoptotic effect of miR-183-5p and Polo-Like kinase 1 inhibitor NMS-P937 in breast cancer cells
Masahisa Kudo
Nicole Zalles
Rosario Distefano
Giovanni Nigita
Dario Veneziano
Pierluigi Gasparini
Carlo M. Croce
Cell Death & Differentiation, 2022, 29 : 407 - 419
[9] 3D-QSAR Studies on 4,5-Dihydro-1H-pyrazolo [4,3-h] Quinazolines as Plk-1, CDK2/A and Aur-A Serine/Threonine Kinase Inhibitors
Bhongade, Bhoomendra A.
Amnerkar, Nikhil D.
Gadad, Andanappa K.
LETTERS IN DRUG DESIGN & DISCOVERY, 2020, 17 (04) : 388 - 395
[10] Synthesis and SAR of new pyrazolo[4,3-h]quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors
Caldarelli, Marina
Angiolini, Mauro
Disingrini, Teresa
Donati, Daniele
Guanci, Marco
Nuvoloni, Stefano
Posteri, Helena
Quartieri, Francesca
Silvagni, Marco
Colombo, Riccardo
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (15) : 4507 - 4511

← 1 2 3 4 5 →